News and Insights
Due to its high mortality and morbidity rates, ovarian cancer remains one of the most challenging diseases to manage. However, significant progress in genomic testing has helped to identify patient-specific tumor characteristics, enabling clinicians to …
Dr. Sadie Dobrozsi, medical director of genetic testing and oncology imaging at Evolent, joined Healio's Oncology Overdrive podcast to explore how advances in genomics and precision medicine are reshaping oncology and driving more patient-centered, …
To better manage oncology drug spending, first consider the factors pushing it ever higher. Health plans know that oncology costs are rising fast, but a recent IQVIA report put numbers to it: Cancer drug spending increased nearly 16% in 2024. What’s …
The combination of patient engagement and clinical decision support can unlock value across the cancer journey. By Dr. Von Nguyen This spring, a health plan member undergoing cancer treatment was struggling. Several rounds of chemotherapy and radiation …
Providers can leverage predictive genomics not only to assess a person’s risk of developing cancer, but also to guide treatment decisions when cancer develops. Dr. Sadie Dobrozsi, Evolent’s medical director for genetic testing and oncology, joined the …
Dr. Kamal Golla, Evolent’s vice president of clinical technologies and performance, joined the Empowered Patient Podcast to talk about the value of care navigation for people with cancer. He explains how care navigation helps people not only take on their …
Evolent and American Oncology Network unveil innovative model to improve cancer care …
Joining Evolent this summer as chief clinical officer, Dr. David Lim brings a background as a physician, executive and startup entrepreneur with experience in value-based care. Most recently, Dr. Lim was chief medical officer and employee number-one at …
Evolent oncology experts have devised a novel metric to help guide decisions about which regimens to include on clinical pathways. If the FDA’s Accelerated Approval Program were an academic course, it would be graded pass-fail. Some therapies ace the …
How much time do cancer patients spend in healthcare settings, and how can we decrease it? By Andrew Hertler, MD, FACP When a patient has incurable metastatic cancer, time is exceedingly valuable. The concept of the “time toxicity” of cancer treatment has …